Abstract: A wire cable construct including a plurality of strands each made of a plurality of wire filaments, the strands and wire filaments arranged in a 37×7 configuration of 37 strands of 7 wire filaments each, with the strands arranged in four layers including a first, central layer of a single strand, a second layer of six strands, a third layer of twelve strands and a fourth, outermost layer of eighteen strands. The cable may have a small diameter for use in medical device applications, and the strand and wire element configuration allows the cable to carry high axial loads, minimizes bending stress when the cable is routed around a tight turn such as a small pulley, and minimizes torsion in the cable due to axial loading.

Abstract: Ultra-High-Strength (UHS) wires are suited to high strength wire, strands, cables and rope applications including robotics force transmission and other high-performance mono- and multifilament wire applications. The wires exhibit high strength, low stretch and fatigue durability. Exemplary UHS materials include binary molybdenum-rhenium or tungsten-rhenium alloys with between 20 and 50 wt. % rhenium. These alloys are processed from a moderate strength (<2 GPa) warm-drawn rod to drawn monofilament wire with extreme nanocrystalline grain refinement, high apparent fatigue durability, and ultimate strength levels exceeding 5 GPa in all cases, and up to 6.8 GPa at monofilament diameters ranging from 7 to 100 ?m.

Abstract: A swaged fitting can be fixed to a wire rope while simultaneously providing a desired shape and size, thereby avoiding the need for subsequent material removal. In one application, the swaged fitting is fixed to the wire rope by a forging operation such that the fitting is securely fixed provides a straight-sided construct once fixed to the wire rope. After the forging operation and without further material removal, the straight sides of the finished fitting are generally parallel to the longitudinal axis of the wire rope, while the end surfaces of the fitting are generally perpendicular to this longitudinal axis. This arrangement provides a strong and effective force-transfer interface for, e.g., end-effectors in medical devices.

Abstract: Multi-filament microcables are used in place of the traditional monofilament wires as the constituent elements of a woven or braided band. This enhances the function and manufacturability of such bands for various applications, such as orthopaedic applications including sternotomy closures.

Abstract: A wire cable construct including a plurality of strands each made of a plurality of wire filaments, the strands and wire filaments arranged in a 37×7 configuration of 37 strands of 7 wire filaments each, with the strands arranged in four layers including a first, central layer of a single strand, a second layer of six strands, a third layer of twelve strands and a fourth, outermost layer of eighteen strands. The cable may have a small diameter for use in medical device applications, and the strand and wire element configuration allows the cable to carry high axial loads, minimizes bending stress when the cable is routed around a tight turn such as a small pulley, and minimizes torsion in the cable due to axial loading.

Abstract: A swaged fitting can be fixed to a wire rope while simultaneously providing a desired shape and size, thereby avoiding the need for subsequent material removal. In one application, the swaged fitting is fixed to the wire rope by a forging operation such that the fitting is securely fixed provides a straight-sided construct once fixed to the wire rope. After the forging operation and without further material removal, the straight sides of the finished fitting are generally parallel to the longitudinal axis of the wire rope, while the end surfaces of the fitting are generally perpendicular to this longitudinal axis. This arrangement provides a strong and effective force-transfer interface for, e.g., end-effectors in medical devices.

Abstract: Multi-filament microcables are used in place of the traditional monofilament wires as the constituent elements of a woven or braided band. This enhances the function and manufacturability of such bands for various applications, such as orthopaedic applications including sternotomy closures.

Abstract: Compounds useful for the inhibition of macrophage migration inhibitory factor (MIF) are provided herein, having the Formula I: wherein A is selected from the group consisting of aromatic or non-aromatic rings, bicyclic rings, polycyclic rings, alkenes or alkynes; B is H, OH, OR, SR, NH2, NHR, or alkyl; R is H or alkyl, and X and Y are independently N or CH, but one of X and Y must be N. Also provided are pharmaceutical compositions that contain a Formula I compound and methods for the treatment of MIF-implicated diseases or conditions that include administering a safe and effective amount of a Formula I compound.

Abstract: Compounds useful for the inhibition of macrophage migration inhibitory factor (MIF) are provided herein, having the Formula I: wherein A is selected from the group consisting of aromatic or non-aromatic rings, bicyclic rings, polycyclic rings, alkenes or alkynes; B is H, OH, OR, SR, NH2, NHR, or alkyl; R is H or alkyl, and X and Y are independently N or CH, but one of X and Y must be N. Also provided are pharmaceutical compositions that contain a Formula I compound and methods for the treatment of MIF-implicated diseases or conditions that include administering a safe and effective amount of a Formula I compound.

Abstract: Compounds useful for the inhibition of macrophage migration inhibitory factor (MIF) are provided herein, having the Formula (I): wherein A is selected from the group consisting of aromatic or non-aromatic rings, bicyclic rings, polycyclic rings, alkenes or alkynes; B is H, OH, OR, SR, NH2, NHR, or alkyl; R is H or alkyl, and X and Y are independently N or CH, but one of X and Y must be N. Also provided are pharmaceutical compositions comprising a Formula I compound and methods for the treatment of MIF-implicated diseases or conditions, comprising administering a safe and effective amount of a Formula I compound.

Abstract: Methods for modulating eye damage associated with a disease or disorder, and/or damage incident to trauma including but not limited to trauma associated with ocular surgery are provided. In some embodiments, the methods include administering an effective amount of a modulator of a migration inhibitory factor (MIF) polypeptide biological activity to a subject. Also provided are methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of an ocular disease, and methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of scarring and/or other consequence of wound healing incident to ocular surgery, as well as modulating the survival, function, and/or differentiation of engrafted cells that can be employed as part of tissue engineering procedures to correct structural, functional, and/or cellular defects of the eye.

Abstract: Methods of inhibiting one or more biological activities of Macrophage migration inhibitory factor (MIF) polypeptides are provided using an MIF inhibitory compound. The methods include therapeutic methods for treating cancers and inflammatory diseases.

Abstract: Methods for modulating eye damage associated with a disease or disorder, and/or damage incident to trauma including but not limited to trauma associated with ocular surgery are provided. In some embodiments, the methods include administering an effective amount of a modulator of a migration inhibitory factor (MIF) polypeptide biological activity to a subject. Also provided are methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of an ocular disease, and methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of scarring and/or other consequence of wound healing incident to ocular surgery, as well as modulating the survival, function, and/or differentiation of engrafted cells that can be employed as part of tissue engineering procedures to correct structural, functional, and/or cellular defects of the eye.

Abstract: Compounds useful for the inhibition of macrophage migration inhibitory factor (MIF) are provided herein, having the Formula (I): wherein A is selected from the group consisting of aromatic or non-aromatic rings, bicyclic rings, polycyclic rings, alkenes or alkynes; B is H, OH, OR, SR, NH2, NHR, or alkyl; R is H or alkyl, and X and Y are independently N or CH, but one of X and Y must be N. Also provided are pharmaceutical compositions comprising a Formula I compound and methods for the treatment of MIF-implicated diseases or conditions, comprising administering a safe and effective amount of a Formula I compound.

Abstract: The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF.

Abstract: The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF.

Abstract: Methods of inhibiting one or more biological activities of Macrophage migration inhibitory factor (MIF) polypeptides are provided using an MIF inhibitory compound. The methods include therapeutic methods for treating cancers and inflammatory diseases.

Abstract: The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF.

Abstract: The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.

Abstract: An apparatus and method is provided for facilitating ionization of a gas medium of a laser gyroscope. The apparatus and method employ a solid state light emitting device as a start aid for the laser gyroscope. The solid state light emitting device has a wavelength at or below a threshold wavelength based on a work function of a cathode coating material to prompt ionization of a gas medium within the laser gyroscope.